These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16289903)

  • 21. Non-preventable mumps outbreaks in schoolchildren in Catalonia.
    Cardeñosa N; Domínguez A; Camps N; Martínez A; Torner N; Navas E; Salleras L
    Scand J Infect Dis; 2006; 38(8):671-4. PubMed ID: 16857613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity.
    Kim SS; Han HW; Go U; Chung HW
    Vaccine; 2004 Dec; 23(3):290-7. PubMed ID: 15530670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.
    Ong G; Goh KT; Ma S; Chew SK
    J Infect; 2005 Nov; 51(4):294-8. PubMed ID: 16291282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Mumps in Poland in 2005].
    Stefanoff P
    Przegl Epidemiol; 2007; 61(2):195-8. PubMed ID: 17956031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children.
    Castilla J; García Cenoz M; Arriazu M; Fernández-Alonso M; Martínez-Artola V; Etxeberria J; Irisarri F; Barricarte A
    Vaccine; 2009 Mar; 27(15):2089-93. PubMed ID: 19356610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mumps in Poland in 2007].
    Paradowska-Stankiewicz I; Orlíková H; Rudowska J
    Przegl Epidemiol; 2009; 63(2):173-5. PubMed ID: 19799239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outbreak of measles in primary school students with high first dose MMR vaccination coverage.
    Ong G; Rasidah N; Wan S; Cutter J
    Singapore Med J; 2007 Jul; 48(7):656-61. PubMed ID: 17609829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination.
    Jokinen S; Osterlund P; Julkunen I; Davidkin I
    J Infect Dis; 2007 Sep; 196(6):861-7. PubMed ID: 17703416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mumps outbreak in the Republic of Moldova, 2007-2008.
    Schwarz NG; Bernard H; Melnic A; Bucov V; Caterinciuc N; an der Heiden M; Andrews N; Pebody R; Aidyralieva C; Hahné S
    Pediatr Infect Dis J; 2010 Aug; 29(8):703-6. PubMed ID: 20308934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mumps: a year of enhanced surveillance in Catalonia, Spain.
    Dominguez A; Oviedo M; Torner N; Carmona G; Costa J; Caylà J; Sala MR; Barrabeig I; Camps N; Minguell S; Alvarez J; Godoy P; Jansà JM;
    Vaccine; 2009 May; 27(25-26):3492-5. PubMed ID: 19460603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine-preventable diseases on college campuses: the emergence of mumps.
    Williams WW; Sosin DM; Kaplan KM; Hersh BS; Preblud SR
    J Am Coll Health; 1989 Mar; 37(5):197-203. PubMed ID: 2703603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule.
    Gay N; Miller E; Hesketh L; Morgan-Capner P; Ramsay M; Cohen B; Brown D
    Commun Dis Rep CDR Rev; 1997 Feb; 7(2):R21-6. PubMed ID: 9046125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of the mumps component of the MMR vaccine: a case control study.
    Harling R; White JM; Ramsay ME; Macsween KF; van den Bosch C
    Vaccine; 2005 Jul; 23(31):4070-4. PubMed ID: 15950329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outbreak of mumps in a vaccinated child population: a question of vaccine failure?
    Vandermeulen C; Roelants M; Vermoere M; Roseeuw K; Goubau P; Hoppenbrouwers K
    Vaccine; 2004 Jul; 22(21-22):2713-6. PubMed ID: 15246601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    Ovsyannikova IG; Pankratz VS; Vierkant RA; Jacobson RM; Poland GA
    J Infect Dis; 2006 Mar; 193(5):655-63. PubMed ID: 16453260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.